{"id":"W2508843946","doi":"10.1016/j.thromres.2016.08.013","title":"Ciraparantag for enoxaparin reversal: Adding to the evidence","year":2016,"lang":"en","type":"editorial","venue":"Thrombosis Research","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Population Health Research Institute; McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"","keywords":"Dabigatran; Rivaroxaban; Apixaban; Medicine; Edoxaban; Heparin; Low molecular weight heparin; Pharmacology; Chemistry; Internal medicine; Warfarin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005786048,0.000286603,0.0007283497,0.0005084418,0.0004836663,0.0001647816,0.0007549873,0.0004716593,0.0004989047],"category_scores_gemma":[0.01759536,0.0001675474,0.0003578974,0.0006849996,0.0001668467,0.0001521123,0.000548177,0.0007919286,0.001236071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004519312,"about_ca_system_score_gemma":0.0005101761,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001420291,"about_ca_topic_score_gemma":0.00004241756,"domain_scores_codex":[0.9949171,0.0003361802,0.0004771767,0.0007224561,0.002699101,0.0008479651],"domain_scores_gemma":[0.9850636,0.01239162,0.0001175359,0.001076423,0.001124187,0.000226595],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005842653,0.000005304491,0.0003182923,0.0003642547,0.0002139545,0.000001834846,0.0001748651,8.940626e-7,0.001017395,0.0003386037,0.9928747,0.004105636],"study_design_scores_gemma":[0.0007969748,0.0004722636,0.001117583,0.001679502,0.0001760792,2.431175e-7,0.00008143063,0.00001059624,0.0001997323,0.0001472812,0.9951127,0.0002056715],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.0004399656,0.00143739,0.0008873777,0.06529205,0.91583,0.008897183,0.0002641982,0.0002261611,0.006725683],"genre_scores_gemma":[0.002725082,0.002483431,0.0005244514,0.0001324636,0.9455634,0.00018486,0.00009833479,0.0001089803,0.04817894],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.06515959,"threshold_uncertainty_score":0.9995416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4059603917357699,"score_gpt":0.552289230322627,"score_spread":0.1463288385868571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}